Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018

被引：0

作者：

Ashleigh McGirr

Shehzad M. Iqbal

Jan Olbrecht

Lijoy Varghese

机构：

[1] GSK,

[2] GSK,undefined

[3] GSK,undefined

来源：

Infectious Diseases and Therapy | 2018年 / 7卷

关键词：

Canada; Cost-effectiveness; Invasive pneumococcal disease; PCV-13; PHiD-CV; Pneumococcal conjugate vaccines;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：535 / 538

页数：3